Bristol-Myers Squibb BMY Abraxane — Total Revenues

Other product segments

Similar metrics at other companies

PFEIbrance — Revenues:

$1.01B+3.2%

EXELCABOMETYX — Total revenues

$552.77M+8.2%

RFL

RFLProduct Revenue — Revenue

$89K-63.4%

SUPNAPOKYN — Total revenues

$7.73M-48.4%

AMGNRepatha — Total revenues

$876M+33.5%

PFEAll other Oncology — Revenues:

$376M-0.3%

Questions, answered.

What is Bristol-Myers Squibb's abraxane — total revenues?

Bristol-Myers Squibb (BMY) reported abraxane — total revenues of $55M in Q2 2026.

How has Bristol-Myers Squibb's abraxane — total revenues changed year-over-year?

Bristol-Myers Squibb's abraxane — total revenues decreased by 47.6% year-over-year, from $105M to $55M.

What is the long-term trend for Bristol-Myers Squibb's abraxane — total revenues?

Over 4 years (2021 to 2025), Bristol-Myers Squibb's abraxane — total revenues has grown at a -25.3% compound annual growth rate (CAGR), from $1.18B to $368M.

What does abraxane — total revenues mean?

This metric represents the total global net sales generated from the commercialization of Abraxane, a chemotherapy medication used primarily for the treatment of breast, pancreatic, and non-small cell lung cancers. As a key oncology asset, revenue performance here reflects the product's market penetration, competitive positioning against generic alternatives, and the impact of patent expirations or regulatory exclusivity. It serves as a critical indicator of the company's legacy oncology portfolio strength and its ability to maintain market share in the mature chemotherapy space.